Pfizer Divests Select China Prevenar 13 Rights, Staff As Domestic Firms Gain Traction

Competitive Presence Needed

 
• By Brian Yang

Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.

A woman wears a facemask as she walks by the Pfizer world headquarters in New York on November 9, 2020.
Pfizer divests China Prevenar 13 rights to local partner amid strong competition, scale challenges • Source: KENA BETANCUR/AFP via Getty Images (KENA BETANCUR/AFP via Getty Images)

More from China

More from Focus On Asia